Dyne Therapeutics, Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD

26.44

+0.19 (0.72%)

Aug 10, 2026, 3:14 PM EDT - Market open

Dyne Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	91.25	69.85	62.48	31.4	28.2	28.72
Research & Development	445.71	398.33	281.41	210.76	142.76	121.31
Total Operating Expenses	536.96	468.18	343.89	242.16	170.96	150.03
Operating Income	-536.96	-468.18	-343.89	-242.16	-170.96	-150.03
Interest Income	32.68	29.86	26.92	7.64	2.92	0.74
Interest Expense	-14.9	-6.19	-0.45	-1.42	-	-
Other Non-Operating Income (Expense)	-0.23	-1.7	-	-	-	-0.01
Total Non-Operating Income (Expense)	13.38	21.97	26.47	6.23	-0.05	0.73
Pretax Income	-523.58	-446.21	-317.42	-235.94	-171.02	-149.29
Net Income	-523.58	-446.21	-317.42	-235.94	-171.02	-149.29
Net Income to Common	-519.41	-446.21	-317.42	-235.94	-168.1	-149.29
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	155	128	94	60	52	51
Shares Outstanding (Diluted)	155	128	94	60	52	51
Shares Change	45.30%	36.43%	57.74%	14.83%	2.13%	253.54%
EPS (Basic)	-3.33	-3.47	-3.37	-3.95	-3.23	-2.93
EPS (Diluted)	-3.33	-3.47	-3.37	-3.95	-3.23	-2.93
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-480.43	-423.92	-294.75	-188.89	-156.71	-123.18
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-3.10	-3.30	-3.13	-3.16	-3.02	-2.42
EBITDA	-534.8	-466.14	-342.21	-240.49	-169.28	-148.94
EBIT	-536.96	-468.18	-343.89	-242.16	-170.96	-150.03

SEC Filings: 10-K · 10-Q